Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis
Table 5
Effects of treatment on laboratory parameters at day 28.
Parameter
SMT (n = 185)
ALSS (n = 205)
value
Serum bilirubin (mg/dl)
Baseline
22.1 (7.1)
23.2 (6.8)
<0.001
Day 28
15.2 (10.1)
22.8 (10.8)
Change from baseline
−4.4 (9.5)
−6.9 (9.5)
Serum albumin (g/L)
Baseline
33.6 (5.4)
32.1 (5.3)
Day 28
33.8 (7.7)
34.1 (7.3)
Change from baseline
0.2 (4.5)
2.0 (17.3)
0.067
Baseline international normalized ratio
Baseline
2.3 (0.6)
2.3 (0.6)
Day 28
1.7 (0.7)
1.7 (0.7)
Change from baseline
−0.5 (0.7)
−0.5 (0.7)
0.975
Serum creatinine (μmol/L)
Baseline
73.2 (22.7)
70.9 (22.8)
Day 28
72.4 (34.5)
70.8 (25.9)
Change from baseline
−0.8 (34.8)
−0.1 (23.4)
0.088
ALT (IU/L)
Baseline
356.2 (242.5)
367.3 (287.4)
Day 7
60.8 (89.7)
44.9 (26.7)
Change from baseline
−295.4 (293.7)
−322.4 (241.8)
0.085
MELD score
Baseline
25.2 (4.2)
25.4 (4.8)
Day 28
17.7 (9.5)
16.8 (7.8)
Change from baseline
−7.5 (8.2)
−8.6 (6.4)
0.042
SMT, standard medical therapy; ALSS, artificial liver support system; MLED, model for end-stage liver disease.
